Samfara buys Danish controlled-substance drug maker Chr. Olesen Synthesis
What's the deal? London-based life sciences investor SamfaraDealroom has a profile for this one. Try Dealroom → has acquired Chr. Olesen SynthesisDealroom has a profile for this one. Try Dealroom →, a Danish manufacturer of active pharmaceutical ingredients (APIs) and intermediates, the firm announced on October 2, 2026. Terms were undisclosed.
What each side does: Samfara runs majority buyouts of lower mid-market European life sciences companies. Based near Copenhagen, Chr. OlesenDealroom has a profile for this one. Try Dealroom → Synthesis makes controlled-substance APIs used in opioid use disorder treatments and ADHD management, supplying drugmakers across Europe, North America, and the Middle East.
Why now? Mads C. Olesen, chief executive of parent Chr. Olesen, said the time had come for new ownership to take the company forward. The business has grown into a notable player in controlled-substance APIs since its 2011 acquisition, and the cGMP-certified facility has operated since 2015.
What's the endgame? This is Samfara's first pharmaceuticals deal, backed by institutional investors from Europe and North America. Partners Helena Malchione and James Cocker said the company fits their strategy of backing firms "operating in complex niches," with plans to expand into new markets and segments.
What changes? Chief executive Thomas Moestrup stays on and will invest alongside Samfara. Jean-François Hilaire, former CEO of UnitherDealroom has a profile for this one. Try Dealroom →, joins the board as chair. Samfara expects to strengthen the facility's infrastructure and production capacity.
The signal: Controlled-substance APIs are a tightly regulated, hard-to-enter corner of pharma manufacturing — exactly the kind of niche buyout investors chase for defensibility. Samfara's entry signals continued private equity appetite for specialised European life sciences assets.
Read more: third-news.com
Image credit: Generated with Gemini
